Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 11
Submit an article Journal homepage
411
Views
15
CrossRef citations to date
0
Altmetric
Reviews

Developing drug strategies for the neuroprotective treatment of acute ischemic stroke

Antonino TuttolomondoInternal Medicine and Cardio-Angiology Ward, Department of Biomedicine and Internal Medicine, Di.Bi. M.I.S, University of Palermo, Palermo, ItalyCorrespondence[email protected]
,
Rosaria PecoraroInternal Medicine and Cardio-Angiology Ward, Department of Biomedicine and Internal Medicine, Di.Bi. M.I.S, University of Palermo, Palermo, Italy;Emergency Care Unit, Fondazione Istituto S. Raffaele/Giglio of Cefalù, Cefalù, Italy
,
Valentina ArnaoNeurology Ward, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
,
Rosario MaugeriNeurosurgery Ward, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
,
Domenico Gerardo IacopinoNeurosurgery Ward, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
&
Antonio PintoInternal Medicine and Cardio-Angiology Ward, Department of Biomedicine and Internal Medicine, Di.Bi. M.I.S, University of Palermo, Palermo, Italy
Pages 1271-1284 | Published online: 15 Oct 2015

References

  • Dirnagl, U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–397.
  • Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003;4(5):399–415.
  • Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA. 2015;313(14):1451–1462.
  • Yam PS, Dunn LT, Graham DI, et al. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia. J Cereb Blood Flow Metab. 2000;20:772–779.
  • Castillo J, Davalos A, Lema M, et al. Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts. Cerebrovasc Dis. 1997;7:245–250.
  • Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke. 2001;32:669–674.
  • Javitt DC, Zukin SR. The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci. 1990;2:44–52.
  • Sims NR, Zaidan E. Biochemical changes associated with selective neuronal death following short-term cerebral ischemia. Int J Biochem Cell Biol. 1995;27:531–550.
  • Dhawan J, Benveniste H, Luo Z, et al. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol. 2011;6(6):823–834.

*an article highlighting the role of glutamate blocking in neuroprotection after stroke

  • Jang JY, Choi YW, Kim HN, et al. Neuroprotective effects of a novel single compound 1-methoxyoctadecan-1-ol isolated from Uncaria sinensis in primary cortical neurons and a photothrombotic ischemia model. PLoS One. 2014;9(1):e85322.
  • Davis SM, Albers GW, Diener HC, et al. Termination of acute stroke studies involving Selfotel treatment. ASSIST Steering Committed. Lancet. 1997;349:32.
  • Sveinbjornsdottir S, Sander JW, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 1993;16:165–174.
  • Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-con-trolled trial. Lancet Neurol. 2012;11:942–950.
  • Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31(11):2543–2551.
  • Weiser T. AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs? Curr Pharm Des. 2002;8(10):941–951.
  • Szénási G, Vegh M, Szabo G, et al. 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochem Int. 2008;52(1–2):166–183.
  • Denes L, Szilágyi G, Gál A, et al. Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Brain Res Bull. 2006;70(3):260–262.
  • Erdo F, Berzsenyi P, Andrási F. The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia. Brain Res Bull. 2005;66(1):43–49.
  • Chen Z, Xiong C, Pancyr C, et al. Prolonged adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical ischemia facilitates clathrin-mediated AMPA receptor endocytosis and long-lasting synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential regulation of GluA2 and GluA1 subunits by p38 MAPK and JNK. J Neurosci. 2014;34(29):9621–9643.
  • Lodder J, Luijckx GJ, van Raak L, et al. Diazepam treatment to increase the cerebral GABAergic activity in acute stroke: a feasibility study in 104 patients. Cerebrovasc Dis. 2000;10:437–440.
  • Lyden PD, Ashwood T, Claesson L, et al. The clomethiazole acute stroke study in ischemic, hemorrhagic, and t-PA treated stroke: design of a phase III trial in the United States and Canada. J Stroke Cerebrovasc Dis. 1998;7:435–441.
  • Xu J, Li C, Xh Y, et al. Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology. 2008;54(7):1029–1040.
  • Zhang F, Li C, Wang R, et al. Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion. Neuroscience. 2007;150(4):938–949.
  • Maples KR, Green AR, Floyd RA. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs. 2004;18(15):1071–1084.
  • Saito K, Kobayashi C, Ikeda M. Effect of radical scavenger N-tert-butyl-alpha-phenylnitrone on stroke in a rat model using a telemetric system. J Pharm Pharm Sci. 2008;11(4):25–31.
  • Zhao Z, Cheng M, Maples KR, et al. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res. 2001;909(1–2):46–50.
  • Del Zoppo G, Ginis I, Hallenbeck JM, et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and i-NOS in brain response to ischemia. Brain Pathol. 2000;10:95.
  • Ferrarese C, Mascarucci P, Zoia C, et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab. 1999;19:1004–1009.
  • Tuttolomondo A, Pecoraro R, Casuccio A, et al. Peripheral frequency of CD4+ CD28- cells in acute ischemic stroke: relationship with stroke subtype and severity markers. Medicine (Baltimore). 2015;94(20):e81.
  • Tuttolomondo A, Di Raimondo D, Di Sciacca R, et al. Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome. Atherosclerosis. 2012;225(1):216–219.
  • Pinto A, Tuttolomondo A, Di Raimondo D, et al. Risk factors profile and clinical outcome of ischemic stroke patients admitted in a Department of Internal Medicine and classified by TOAST classification. Int Angiol. 2006;25(3):261–267.
  • Licata G, Tuttolomondo A, Corrao S, et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke, association with time of onset and diabetic state. Int J Immunopathol Pharmacol. 2006;19(3):639–646.
  • Pinto A, Tuttolomondo A, Di Raimondo D, et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metab. 2008;57(5):676–682.
  • Pinto A, Di Raimondo D, Tuttolomondo A, et al. Effects of physical exercise on inflammatory markers of atherosclerosis. Curr Pharm Des. 2012;18(28): 4326–4349.
  • Brifault C, Gras M, Liot D, et al. Delayed pituitary adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m2 microglia/macrophage polarization. Stroke. 2015;46(2):520–528.
  • Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051–1070.
  • Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab. 2012;32(10):1933–1938.

**a revolutionary anti-inflammatory strategy in stroke neuroprotection

  • Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32:553–56.

*The first article showing a broad potential therapeutic window of albumin in neuroprotection

  • Zoellner H, Höfler M, Beckmann R, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci. 1996;109:2571–2580.
  • Belayev L, Zhao W, Pattany PM, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29:2587–2599.
  • Liu Y, Belayev L, Zhao W, et al. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol. 2001;428:193–201.
  • Tang J, Li YJ, Mu J, et al. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic injury in rats. Neurol Res. 2009;31:189–194.
  • Ginsberg MD, Palesch YY, Hill MD, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013;12(11):1049–1058.
  • Ginsberg MD, Hill MD, Palesch YY, et al. A dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: physiological responses and safety results. Stroke. 2006;37:2100–2106.
  • Ginsberg MD, Palesch YY, Martin RH, et al. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke. 2011;42(1):119–127.
  • Yang Y, Li Q, Ahmad F, et al. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett. 2000;285:119–122.
  • Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev. 2003;Issue 3. Art. No.: CD001244. DOI:10.1002/14651858.
  • Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (IMAGES trial): randomised controlled trial. Lancet. 2004;363:439–445.
  • Saver JL, Starkman S, Eckstein M, et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med. 2015;372(6):528–536.
  • Aslanyan S, Weir CJ, Muir KW, et al Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke. 2007;38:1269–73.

**an article showing a possible role of magnesium in neuroprotection after lacunar stroke

  • Krupinski J, Ferrer I, Barrachina M, et al. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. 2002;42:846–854.
  • Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res. 2001;893:268–272.
  • Andersen M, Overgaard K, Meden P, et al. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke. 1999;30:1464–1471.
  • Clark WM, Wechsler LR, Sabounjian LA, et al. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001;57:1595–1602.
  • Dávalos A, Alvarez-Sabín J, Castillo J, et al.Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349–357.

**an article reporting promising prospectives with regard of role of Citicoline as neuroprotectant

  • Hartwig K, Fackler V, Jaksch-Bogensperger H, et al. Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3β signaling. Int J Dev Neurosci. 2014;38:52–58.
  • Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, et al. Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatr Dis Treat. 2014;10:2299–2306.
  • Heiss WD, Brainin M, Bornstein NM, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630–636.

**this article report about the most promising neuroprotectant agent

  • Tikka T, Koistinaho J. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001;166:7527–7533.
  • Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21: 2580–2588.
  • Tikka T, Vartiainen N, Goldsteins G, et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neuron disease. Brain. 2002;125:722.
  • Wang CX, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 2003;963:239–327.
  • Xu L, Fagan SC, Waller JL, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion - reperfusion in rats. BMC Neurol. 2004;4:7–13.
  • Xu L, Fagan SC, Waller J, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004;4(1):731.
  • Fagan SC, Waller JL, Nichols FT, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010;41(10):2283–2287.
  • Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke. Neurology. 2007;69(14):1404–1410.
  • Yang Y, Rosenberg GA. Matrix metalloproteinases as therapeutic targets for stroke. Brain Res. 2015;1623:30–38.
  • Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6:484–494.
  • Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004;31:129–142.
  • Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8(8):495–505.
  • Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647–56.
  • Guglielmo MA, Chan PT, Cortez S, et al. The temporal profile and morphologic features of neuronal death in human stroke resemble those observed in experimental forebrain ischemia: the potential role of apoptosis. Neurol Res. 1998;20:283–296.
  • Furukawa K, Smith-Swintosky VL, Mattson MP. Evidence that actin depolymerization protects hippocampal neurons against excitotoxicity by stabilizing [Ca 2+]. Exp Neurol. 1995;133:153–16.
  • O’Connell J, Houston A, Bennett MW, et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nature Med. 2001;7:271–274.
  • Love S, Barber R, Wilcock GK. Apoptosis and expression of DNA repair proteins in ischaemic brain injury in man. Neuroreport. 1998;9:955–995.
  • Mattson MP, Furukawa K. Programmed cell life: anti-apoptotic signaling and therapeutic strategies for neurodegenertive disorders. Restorative Neurol Neurosci. 1996;9:191–20.
  • Mattson MP. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci. 1998;21: 53–55.
  • Cheng B, Mattson MP. IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci. 1992;12:1558–1566.
  • Sairanen T, Karjalainen-Lindsberg ML, Paetau A, et al. Apoptosis dominant in the periinfarct area of human ischaemic stroke–a possible target of antiapoptotic treatments. Brain. 2006;129(Pt 1):189–199.
  • Mühl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol. 2003;3(9): 1247–1255.
  • Friedrich MA, Martins MP, Araújo MD, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21(Suppl 1):S13–21.
  • Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012;43(8):2242–2243.
  • Banerjee S, Bentley P, Hamady M, et al. Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Transl Med. 2014;3(11):1322–1330.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.